Censa Pharmaceuticals   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2015)
Status: Acquired by PTC Therapeutics (2020)

Organization Overview

First Clinical Trial
2018
NCT03519711
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Censa Pharmaceuticals | Censa Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

sepiapterin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gastroparesis (Phase 2)

Phenylketonurias (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1